

Oklahoma Health Care Authority

Drug Utilization Review Board

(DUR Board)

Meeting – July 14, 2021 @ 4:00pm

at the

Oklahoma Health Care Authority (OHCA)

4345 N. Lincoln Blvd.

Oklahoma City, Oklahoma 73105

NOTE: *The DUR Board will meet at 4:00pm at OHCA (see address above). There will be Zoom access to this meeting; however, Zoom access will be set up in view-only mode with no voting, speaking, video, or chat box privileges. Zoom access will allow for viewing of the presentation slides as well as audio of the presentations and discussion during the meeting; however, the DUR Board meeting will not be delayed or rescheduled due to any technical issues that may arise.*

AGENDA

Discussion and action on the following items:

Items to be presented by Dr. Muchmore, Chairman:

1. Call to Order

A. Roll Call – Dr. Wilcox

DUR Board Members:

Dr. Stephen Anderson –	participating in person
Dr. Jennifer de los Angeles –	participating in person
Ms. Jennifer Boyett –	participating in person
Dr. Markita Broyles –	participating in person
Dr. Megan Hanner –	participating in person
Dr. Lynn Mitchell –	participating in person
Dr. John Muchmore –	participating in person
Dr. Lee Muñoz –	participating in person
Dr. James Osborne –	participating in person

Viewing Access Only via Zoom:

Please register for the meeting at:

https://zoom.us/webinar/register/WN_D0er6gVIR8mZvxCOmI3BGg

After registering, you will receive a confirmation email containing information about joining the webinar.

Or join by phone:

Dial: +1-602-753-0140 or +1-669-219-2599

Webinar ID: 922 6217 2322

Passcode: 98317667

Public Comment for Meeting:

- Speakers who wish to sign up for public comment at the OHCA DUR Board meeting may do so in writing by visiting the DUR Board page on the OHCA website at www.oklahoma.gov/ohca/about/boards-and-committees/drug-utilization-review/dur-board and completing the [Speaker Registration Form](#). Completed Speaker Registration forms should be submitted to DURPublicComment@okhca.org. Forms must be received after the DUR Board agenda has been posted and no later than 24 hours before the meeting.
- The DUR Board meeting will allow public comment and time will be limited to 40 minutes total for all speakers during the meeting. Each speaker will be given 5 minutes to speak at the public hearing. If more than 8 speakers properly request to speak, time will be divided evenly.
- Only 1 speaker per manufacturer will be allowed.
- Any speakers who sign up for public comment must attend the DUR Board meeting in person at OHCA (see above address). Public comment through Zoom will not be allowed for the DUR Board meeting.

Items to be presented by Dr. Muchmore, Chairman:

2. Public Comment Forum

- A. Acknowledgment of Speakers for Public Comment

Items to be presented by Dr. Muchmore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A

- A. June 9, 2021 DUR Minutes – Vote
- B. June 9, 2021 DUR Recommendation Memorandum

Items to be presented by Dr. Wilson, Dr. Nawaz, Dr. Muchmore, Chairman:

4. Update on Medication Coverage Authorization Unit/Chronic Medication Adherence (CMA) Program Update – See Appendix B

- A. Pharmacy Helpdesk Activity for June 2021
- B. Medication Coverage Activity for June 2021
- C. CMA Program Update

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

5. Vote to Prior Authorize Lybalvi™ (Olanzapine/Samidorphane) – See Appendix C

- A. Market News and Updates
- B. Lybalvi™ (Olanzapine/Samidorphane) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

6. Action Item – Vote to Prior Authorize Azstarys™ (Serdexmethylphenidate/Dexmethylphenidate), Qelbree™ (Viloxazine), and Xywav™ (Calcium/Magnesium/Potassium/Sodium Oxybates) – See Appendix D

- A. Market News and Updates
- B. Product Summaries
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Ha, Dr. Muchmore, Chairman:

7. Action Item – Vote to Prior Authorize Helidac® Therapy (Bismuth Subsalicylate/Metronidazole/Tetracycline Dose Pack) and Pylera® (Bismuth Subcitrate Potassium/Metronidazole/Tetracycline Capsule) – See Appendix E

- A. Market News and Updates
- B. *Helicobacter Pylori* (*H. Pylori*) Product Summaries
- C. Cost Comparison: *H. Pylori* Regimens
- D. College of Pharmacy Recommendations

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

8. Action Item – Vote to Prior Authorize Alkindi® Sprinkle (Hydrocortisone Oral Granule), Eysuvis® (Loteprednol 0.25% Ophthalmic Suspension), Gimoti™ (Metoclopramide Nasal Spray), Nextstellis® (Drospirenone/Estetrol Tablet), Ozobax™ (Baclofen 5mg/mL Oral Solution), Phexxi® (Lactic Acid/Citric Acid/Potassium Bitartrate Vaginal Gel), RediTrex™ (Methotrexate Injection), Reltone™ (Ursodiol Capsule), and Thyquidity™ (Levothyroxine Oral Solution) – See Appendix F

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

9. Annual Review of Koselugo™ (Selumetinib), Pemazyre® (Pemigatinib), and Qinlock® (Ripretinib) and 30-Day Notice to Prior Authorize Danyelza® (Naxitamab-gqqk) and Truseltiq™ (Infigratinib) – See Appendix G

- A. Introduction
- B. Current Prior Authorization Criteria
- C. Utilization of Koselugo™ (Selumetinib), Pemazyre® (Pemigatinib), and Qinlock® (Ripretinib)
- D. Prior Authorization of Koselugo™ (Selumetinib), Pemazyre® (Pemigatinib), and Qinlock® (Ripretinib)
- E. Market News and Updates
- F. Product Summaries
- G. College of Pharmacy Recommendations
- H. Utilization Details of Koselugo™ (Selumetinib), Pemazyre® (Pemigatinib), and Qinlock® (Ripretinib)

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

10. Annual Review of Opioid Analgesics and Medication-Assisted Treatment (MAT) Medications and 30-Day Notice to Prior Authorize Qdolo™ (Tramadol 5mg/mL Oral Solution) – See Appendix H

- A. Current Prior Authorization Criteria
- B. Utilization of Opioid Analgesics and MAT Medications
- C. Prior Authorization of Opioid Analgesics and MAT Medications
- D. Market News and Updates
- E. Qdolo™ (Tramadol 5mg/mL Oral Solution) Product Summary
- F. College of Pharmacy Recommendations
- G. Utilization Details of Opioid Analgesics
- H. Utilization Details of MAT Medications

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

11. Annual Review of Topical Corticosteroids and 30-Day Notice to Prior Authorize Impeklo® (Clobetasol Propionate 0.05% Lotion) – See Appendix I

- A. Current Prior Authorization Criteria
- B. Utilization of Topical Corticosteroids
- C. Prior Authorization of Topical Corticosteroids
- D. Market News and Updates
- E. Impeklo® (Clobetasol Propionate 0.05% Lotion) Product Summary
- F. College of Pharmacy Recommendations
- G. Utilization Details of Topical Corticosteroids

Items to be presented by Dr. Ha, Dr. Muchmore, Chairman:

12. Annual Review of Ophthalmic Anti-Inflammatory Products – See Appendix J

- A. Current Prior Authorization Criteria
- B. Utilization of Ophthalmic Anti-Inflammatory Products
- C. Prior Authorization of Ophthalmic Anti-Inflammatory Products
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Ophthalmic Corticosteroids
- G. Utilization Details of Ophthalmic Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

Items to be presented by Dr. Ha, Dr. Muchmore, Chairman:

13. 30-Day Notice to Prior Authorize Nulibry™ (Fosdenopterin) – See Appendix K

- A. Introduction
- B. Nulibry™ (Fosdenopterin) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

14. 30-Day Notice to Prior Authorize Feraheme® (Ferumoxytol), Injectafer® (Ferric Carboxymaltose), and Monoferic® (Ferric Derisomaltose) – See Appendix L

- A. Introduction
- B. Utilization of Intravenous (IV) Iron Products: Medical Claims
- C. Market News and Updates
- D. Product Summaries
- E. Relative Risk of Serious Adverse Effects (SAEs)
- F. Cost Comparison
- G. College of Pharmacy Recommendations
- H. Utilization Details of IV Iron Products

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

15. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix M

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

16. Future Business* (Upcoming Product and Class Reviews)

No DUR Board meeting scheduled for August 2021.

- A. Breast Cancer Medications
- B. Prostate Cancer Medications
- C. Synagis® (Palivizumab)
- D. Targeted Immunomodulator Agents

**Future product and class reviews subject to change.*

17. Adjournment

NOTE: An analysis of the atypical [Aged, Blind, and Disabled (ABD)] patient subgroup of the Oklahoma Medicaid population has been performed pertaining to all recommendations included in this DUR Board meeting packet to ensure fair and knowledgeable deliberation of the potential impact of the recommendations on this patient population.